55 completed. 55 Phase 2, 10 Phase 1, 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 55 | Completed 55 |
| Phase 1 | 10 | Completed 10 |
| Phase 3 | 7 | Completed 7 |
Follow Solutions: new trials by email Literature Review of Solutions trials Research Report on Solutions
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases TAK-881, HYQVIA - Primary Immunodeficiency Diseases (PID) | Phase 2 / Phase 3 | Completed | Takeda | 65 | 2023-10-24 | 2026-09-30 |
| Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC) Aminolevulinic Acid 20% Topical Solution with Blue Light - Facial Cutaneous Squamous Cell Carcinoma in Situ | Phase 2 | Completed | The Center for Clinical and Cosmetic Research | 32 | 2023-08-08 | 2025-02-12 |
| Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men prostaglandin F2a analogue in vehicle solution high dose, prostaglandin F2a analogue in vehicle solution low dose, active ingredient-free vehicle solution to DLQ01 - Androgenetic Alopecia | Phase 1 / Phase 2 | Completed | Dermaliq Therapeutics, Inc. | 120 | 2022-12-05 | 2024-04-08 |
| Efficacy of VTP-300 in Chronic Hepatitis B Infection ChAdOx1-HBV, MVA-HBV, Nivolumab - Chronic Hepatitis B | Phase 2 | Completed | Barinthus Biotherapeutics | 121 | 2022-09-21 | 2026-04-30 |
| JINZHEN for Treatment of Mild to Moderate COVID-19 JINZHEN Granules for Oral Solution, Placebo - COVID-19 | Phase 1 / Phase 2 | Completed | Lianyungang Kanion Group, Ltd. | 60 | 2022-05-26 | 2024-03-20 |
| Comparison of Fluid Resuscitation in Pediatric Burn Patients Using Crystalloids and With Albumin on Day Two. 5% Albumin (human) Solution, Paeds solution - Burns | Phase 2 / Phase 3 | Completed | King Edward Medical University | 90 | 2022-01-01 | 2024-01-25 |
| Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients S95011 concentrate for solution for infusion, Placebo concentrate for solution for infusion - Primary Sjögren's Syndrome | Phase 2 | Completed | Institut de Recherches Internationales Servier | 48 | 2021-08-03 | 2024-04-23 |
| Efficacy and Safety Study of Ketorolac / Pitofenone / Fenpiverinium for the Treatment of Patients With Pain After Surgical Abdominal and Pelvic Operations Ketorolac tromethamine, solution for injection then Neospastil, film-coated tablets, Ketorolac tromethamine, solution for injection then Ketorolac tromethamine, coated tablets, Neospastil, solution for injection then Neospastil, film-coated tablets - Postsurgical Pain | Phase 2 / Phase 3 | Completed | Darnitsa Pharmaceutical Company | 424 | 2021-07-07 | 2022-11-07 |
| CBD for Dental Pain Epidiolex 100 mg/mL Oral Solution, Placebo - Odontalgia, Toothache | Phase 1 / Phase 2 | Completed | The University of Texas Health Science Center at San Antonio | 64 | 2021-03-01 | 2024-05-09 |
| Dexamethasone Solution and Dexamethasone in Mucolox™ dexamethasone 0.5mg/5ml solution, dexamethasone 0.5mg/5ml solution in Mucolox™ - Oral Lichen Planus, Mucous Membrane Pemphigoid | Phase 2 | Completed | University of California, San Francisco | 29 | 2020-12-26 | 2023-12-15 |
| First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV ChAdOx1-HBV, MVA-HBV, Nivolumab - Hepatitis B | Phase 1 / Phase 2 | Completed | Barinthus Biotherapeutics | 55 | 2020-12-22 | 2024-08-13 |
| A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution, Placebo: WST-057 4mL topical solution - Painful Diabetic Neuropathy, Diabetes Mellitus | Phase 2 | Completed | WinSanTor, Inc | 58 | 2020-11-20 | 2023-10-18 |
| The Effect of Perioperative Dexamethasone Administration on Postoperative Pain in Patients Undergoing Periacetabular Osteotomy. Dexamethasone 24mg Solution for Injection, Saline Solution for Injection - Dexamethasone, Hip Dysplasia | Phase 2 / Phase 3 | Completed | Odense University Hospital | 90 | 2020-11-12 | 2024-04-02 |
| Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus Dupilumab 300Mg Solution for Injection - Pruritus | Phase 2 | Completed | Mayo Clinic | 9 | 2020-09-01 | 2025-11-21 |
| Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes - IVORY Interleukin-2 [IL-2], Placebo Dextrose 5% solution - Acute Coronary Syndromes | Phase 2 | Completed | Cambridge University Hospitals NHS Foundation Trust | 60 | 2020-08-05 | 2024-06-10 |
| Therapeutic Effect of Tacrosolv in Patients With Allergic Rhinoconjunctivitis Eye Drops, Solution in Single-Dose Container - Allergic Conjunctivitis, Allergic Rhinitis | Phase 2 | Completed | Marinomed Biotech AG | 64 | 2020-08-04 | 2022-08-25 |
| Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma Dupilumab 300Mg Solution for Injection, Placebo - Localized Scleroderma | Phase 2 | Completed | University of Cologne | 45 | 2020-05-19 | 2024-10-26 |
| Albumin for Management of Hypervolemic Hyponatremia (AlbuCAT) Albumin treatment - Hyponatremia With Excess Extracellular Fluid Volume, Cirrhosis, Liver | Phase 2 | Completed | Fundacion Clinic per a la Recerca Biomédica | 52 | 2020-02-01 | 2025-02-28 |
| IL-1 Signal Inhibition in Alcoholic Hepatitis Canakinumab 150mg/ml solution for injection, Placebo - Alcoholic Hepatitis | Phase 2 | Completed | Imperial College London | 55 | 2019-02-12 | 2025-03-11 |
| Pharmacokinetics of Oral Hydroxyurea Solution Oral Hydroxyurea (100 mg/mL) Solution - Sickle Cell Disease, Sickle-Cell; Hemoglobin Disease, Thalassemia | Phase 1 / Phase 2 | Completed | Nova Laboratories Limited | 33 | 2019-01-03 | 2024-10-28 |
Showing 20 of 55. Sign in to see all of them.
Alopecia (4) · Pain, Postoperative (4) · Pain (3) · Primary Immunodeficiency Diseases (3) · Autoimmune Diseases (2) · Hepatitis B (2) · Keratosis, Actinic (2) · Lichen Planus, Oral (2) · Pemphigoid, Benign Mucous Membrane (2) · Acne Vulgaris (1) · Acute Coronary Syndrome (1) · Agammaglobulinemia (1) · Agnosia (1) · Alcoholism (1) · Alopecia Areata (1)
Allergan (2) · Barinthus Biotherapeutics (2) · Baxalta now part of Shire (2) · DUSA Pharmaceuticals, Inc. (2) · Dompé Farmaceutici S.p.A (2) · AbbVie (prior sponsor, Abbott) (1) · Aclaris Therapeutics, Inc. (1) · Ahmed Hassan Nouh MD (1) · Ain Shams University (1) · Apeptico Forschung und Entwicklung GmbH (1) · Assiut University (1) · BDD Pharma Ltd (1) · Biosplice Therapeutics, Inc. (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Castillo, José, M.D. (1)
United States (25) · Germany (8) · Spain (7) · United Kingdom (7) · France (4) · Denmark (3) · Egypt (3) · Australia (2) · Austria (2) · Canada (2) · Finland (2) · Italy (2) · Poland (2) · Taiwan (2) · Czechia (1)
Stuart Marcus, MD, PhD (2) · Alessandro Villa, DDS, PhD, MPH (1) · Andrew Blauvelt, MD, MBA (1) · Angela E Rankine- Mullings, MD (1) · Angela Hansen (1) · Betsy Hughes-Formella, PhD (1) · Bridgette L. Jones, MD (1) · Claudio Camponovo, MD (1) · Daniel M Stewart, DO (1) · David C Wilson, MD (1) · Dennis Andress (1)
PMID 19620039, PMID 20115946, PMID 21199096, PMID 21712909, PMID 21899919, PMID 25601618, PMID 25765294, PMID 26291554, PMID 26448169, PMID 27215779, PMID 27582171, PMID 30626238, PMID 31228628, PMID 31245963, PMID 31268374, PMID 31321800, PMID 32199492, PMID 32478930, PMID 34036490, PMID 34763711, PMID 36207050, PMID 36519620, PMID 37549933, PMID 38125671, PMID 39181422, PMID 39196191, PMID 39386177, PMID 40460271, PMID 40932107, PMID 41507574
2019 (4), 2017 (2), 2014 (1), R44DK104512 (1)